Publications

Lefever TW, Schwotzer D, Bonn-Miller MO, McDonald J, Henderson RG, Trexler KR. Novel data update on oral toxicity of phytocannabinoids in rats after 14-days repeated dosing. Carolina Cannabinoid Collaborative (CCC) Conference, Greenville, NC, November 2022.

Lefever TW, Trexler KR, Henderson RG, Bonn-Miller MO. Pre-clinical evaluation of cannabidiol toxicity in rats. Poster presented at the 32^nd Annual International Cannabinoid Research Society Symposium on the Cannabinoids, Galway, Ireland, June 2022.

Reichert H, Suh M, Jiang X, Movva N, Bylsma LC, Fryzek JP, Nelson CB. 2022. Mortality associated with respiratory syncytial virus, bronchiolitis, and influenza among infants in the United States: A birth cohort study from 1998 to 2018. J Infect Dis 226(Suppl 2):S246–S254; doi: 10.1093/infdis/jiac127. PMID: 35968877.

Bylsma LC, Suh M, Movva N, Fryzek JP, Nelson CB. 2022. Mortality among United States infants and children under 5 years of age with respiratory syncytial virus and bronchiolitis: A systematic literature review. J Infect Dis 226(Suppl 2):S267–S281; doi: 10.1093/infdis/jiac226. PMID: 35968871.

Movva N, Suh M, Bylsma LC, Fryzek JP, Nelson CB. 2022. Systematic literature review of respiratory syncytial virus laboratory testing practices and incidence in United States infants and children <5 years of age. J Infect Dis 226(Suppl 2):S213–S224; doi: 10.1093/infdis/jiac203. PMID: 35968874.

Suh M, Movva N, Bylsma LC, Fryzek JP, Nelson CB. 2022. A systematic literature review of the burden of respiratory syncytial virus disease and health care utilization among United States infants younger than 1 year. J Infect Dis 226(Suppl 2):S195–S212; doi: 10.1093/infdis/jiac201. PMID: 35968876.

Suh M, Movva N, Jiang X, Reichert H, Bylsma LC, Fryzek JP, Nelson CB. 2022. Respiratory syncytial virus burden and healthcare utilization in United States infants, <1 year of age: Study of nationally representative databases, 2011–2019. J Infect Dis 226(Suppl 2):S184–S194; doi: 10.1093/infdis/jiac155. PMID: 35968879.

Movva N, Suh M, Reichert H, Hitze B, Sendak MP, Wolf Z, et al. 2022. Respiratory syncytial virus during the COVID-19 pandemic compared to historic levels: A retrospective cohort study of a health system. J Infect Dis 226(Suppl 2):S175–S183; doi: 10.1093/infdis/jiac220. PMID: 35968868.

Suh M, Movva N, Jiang X, Bylsma LC, Reichert H, Fryzek JP, Nelson CB. 2022. Respiratory syncytial virus (RSV) is the leading cause of United States infant hospitalizations 2009–2019: A study of the National (Nationwide) Inpatient Sample. J Infect Dis 226(Suppl 2):S154–S163; doi: 10.1093/infdis/jiac120. PMID: 35968878.

Goyak KO, Sarang SS, Franzen A, Borghoff SJ, Ryman-Rasmussen JP. 2022. Adverse outcome pathway (AOP): α2u-globulin nephropathy and kidney tumors in male rats. Crit Rev Toxicol, open access.